Seeking AlphaSeeking Alpha

RespireRx Pharma rises 50% higher on collaboration with NIH for pain treatment

  • RespireRx Pharma (OTCPK:RSPI) is trading 50% higher after the company said it was accepted into the National Institute of Health HEAL Initiative preclinical screening platform for pain program for its lead drug, KRM-II-81, that has shown to be effective in relieving acute, chronic, and neuropathic pain in a number of models without tolerance development or sedation.
  • The NIH HEAL Initiative is a trans-agency effort to speed scientific solutions to stem the national opioid public health crisis.